GH (Guardant Health) GF Value : $40.11 (As of May. 01, 2025)

View and export this data going back to 2018. Start your Free Trial

What is Guardant Health GF Value?

As of today (2025-05-01), Guardant Health's share price is $47.23. Guardant Health's GF Value is $40.11. Therefore, Guardant Health's Price-to-GF-Value for today is 1.18. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Guardant Health is Modestly Overvalued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Guardant Health (NAS:GH) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (1)
Possible Value Trap, Think Twice	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (2)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (2)	Predictable High Quality Companies which are Significantly Undervalued

(1) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(2) A sufficient margin of safety exists only when the stock is undervalued.

Possible Value Trap, Think Twice companies are those that appear significantly undervalued based on their Price-to-GF-Value ratio, but whose fundamentals show signs of weakness.

Indicators that a company may be a value trap include:

    * Deteriorating Financial Health: A low Altman Z-scores indicates a higher risk of bankruptcy, or a low Piotroski F-Score.
    * Earnings Manipulation: A high Beneish M-score indicates potential earnings manipulation, raising concerns about the reliability of reported financials.
    * Stagnant or Declining Growth: Lack of revenue or earnings growth, or a recent slowdown, may signal limited future prospects.

Investors should conduct thorough due diligence, examining financial statements and growth indicators, to avoid falling into value traps.

Guardant Health's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	47.23	/	40.11
	=	1.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guardant Health GF Value Related Terms

Thank you for viewing the detailed overview of Guardant Health's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (NAS:GH) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

GH:Mexico 5GH:Germany

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Executives

Musa Tariq	director	3100 HANOVER STREET, PALO ALTO CA 94304
Kumud Kalia	officer: Chief Information Officer	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Meghan V. Joyce	director	THE BOSTON BEER COMPANY, INC., ONE DESIGN CENTER PL., STE. 850, BOSTON MA 02210
Ian T Clark	director	SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Ines Dahne-steuber	officer: Chief Operating Officer	3100 HANOVER STREET, PALO ALTO CA 94304
Darya Chudova	officer: Chief Technology Officer	3100 HANOVER STREET, PALO ALTO CA 94304
Helmy Eltoukhy	director, officer: Chief Executive Officer	2 BARRY LANE, ATHERTON CA 94027
Amirali Talasaz	director, officer: Chairman, President and COO	18 ISABELLA AVENUE, ATHERTON CA 94027
Amelia Merrill	officer: SVP, People	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Steve E. Krognes	director	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Stanley J Meresman	director	2071 HUNTINGTON LANE, LOS ALTOS CA 94024
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Chris Freeman	officer: Chief Commercial Officer	505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Vijaya Gadde	director	C/O TWITTER INC, 1355 MARKET STREET SUITE 900, SAN FRANCISCO CA 94103
Bahija Jallal	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204